Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 417

Showing 1-25 of 417 citing articles:

Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Sachin S. Shivatare, Vidya S. Shivatare, Chi‐Huey Wong
Chemical Reviews (2022) Vol. 122, Iss. 20, pp. 15603-15671
Open Access | Times Cited: 107
Structure-based drug design with geometric deep learning
Clemens Isert, Kenneth Atz, Gisbert Schneider
Current Opinion in Structural Biology (2023) Vol. 79, pp. 102548-102548
Open Access | Times Cited: 97
Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Chunrong Yang, Yuchen Yang, Yujie Li, et al.
Journal of the American Chemical Society (2022) Vol. 145, Iss. 1, pp. 385-391
Closed Access | Times Cited: 86
Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 68
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 53
Ferroptosis Nanomedicine: Clinical Challenges and Opportunities for Modulating Tumor Metabolic and Immunological Landscape
Huocheng Yang, Xuemei Yao, Yingqi Liu, et al.
ACS Nano (2023) Vol. 17, Iss. 16, pp. 15328-15353
Closed Access | Times Cited: 51
A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced Immunotherapy
Yaping Wu, Xiaowei Chang, Guizhu Yang, et al.
Advanced Materials (2023) Vol. 35, Iss. 12
Open Access | Times Cited: 50
Molecular Glue Discovery: Current and Future Approaches
Jeffrey A. Dewey, Clémence Delalande, Saara‐Anne Azizi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9278-9296
Open Access | Times Cited: 47
Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization
Martin P. Schwalm, Andreas Krämer, Anja Dölle, et al.
Cell chemical biology (2023) Vol. 30, Iss. 7, pp. 753-765.e8
Open Access | Times Cited: 46
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16642-16649
Closed Access | Times Cited: 41
Small molecule approaches to targeting RNA
Sandra Kovachka, Marc Panosetti, Benedetto Grimaldi, et al.
Nature Reviews Chemistry (2024) Vol. 8, Iss. 2, pp. 120-135
Open Access | Times Cited: 33
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 27
Discovery of a PROTAC degrader for METTL3-METTL14 complex
Wenhao Du, Yuting Huang, Xiaoai Chen, et al.
Cell chemical biology (2024) Vol. 31, Iss. 1, pp. 177-183.e17
Closed Access | Times Cited: 24
PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer
Shunan Zhang, Yi Lai, Jiaxing Pan, et al.
Advanced Materials (2024) Vol. 36, Iss. 23
Closed Access | Times Cited: 22
PROTAC technology: From drug development to probe technology for target deconvolution
Si Yan, Guangshuai Zhang, Wei Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116725-116725
Closed Access | Times Cited: 19
Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 18
Cell Membrane as A Promising Therapeutic Target: From Materials Design to Biomedical Applications
Xiaofeng Wu, Jingjing Hu, Juyoung Yoon
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 18
Closed Access | Times Cited: 17
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
Functional Characterization of Pathway Inhibitors for the Ubiquitin-Proteasome System (UPS) as Tool Compounds for CRBN and VHL-Mediated Targeted Protein Degradation
Martin P. Schwalm, Amelie Menge, Lewis Elson, et al.
ACS Chemical Biology (2025) Vol. 20, Iss. 1, pp. 94-104
Open Access | Times Cited: 2
BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
SMARCA2 protein: structure, function and perspectives of drug design
Zhaolin Guo, Peng Wang, Yuxuan Han, et al.
European Journal of Medicinal Chemistry (2025), pp. 117319-117319
Closed Access | Times Cited: 2
Checkpoint Nano‐PROTACs for Activatable Cancer Photo‐Immunotherapy
Chi Zhang, Mengke Xu, Shasha He, et al.
Advanced Materials (2022) Vol. 35, Iss. 6
Closed Access | Times Cited: 67
Targeting ferroptosis: Paving new roads for drug design and discovery
Yilin Gu, Yizhe Li, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115015-115015
Closed Access | Times Cited: 50
Page 1 - Next Page

Scroll to top